Cxcr4 expression is associated with time–course permanent and temporary myocardial infarction in rats

Document Type: Original Article


1 Razi Herbal Medicines Research Center and School of Allied Medical Sciences, Department of Hematology and Blood Transfusion, Lorestan University of Medical Sciences, Khorramabad, Iran

2 Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran

3 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

4 Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

5 Department of Immunology, Lorestan University of Medical Sciences, Khorramabad, Iran

6 Department of Social Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

7 Razi Herbal Medicines Research Center, Department of Physiology, Lorestan University of Medical Sciences, Khorramabad, Iran


Objective(s): Experimental myocardial infarction triggers secretion of Stromal cell-derived factor1 and lead to increase in the expression of its receptor "CXCR4" on the surface of various cells. The aim of this study was to evaluate the expression pattern of CXCR4 in peripheral blood cells following time-course permanent and temporary ischemia in rats.
Materials and Methods: Fourteen male Wistar rats were divided into two groups of seven and were placed under permanent and transient ischemia. Peripheral blood mononuclear cells were isolated at different time points, RNAs extracted and applied to qRT-PCR analysis of the CXCR4 gene. 
Results: Based on repeated measures analysis of variance, the differences in the expression levels of the gene in each of the groups were statistically significant over time (the effect of time) (P-value< 0.001). Additionally, the difference in gene expression between the two groups was statistically significant (the effect of group), such that at all times, the expression levels of the gene were significantly higher in the permanent ischemia than in the transient ischemia group (P-value<0.001). Moreover, the interactive effect of time-group on gene expression was statistically significant (P-value<0.001).
Conclusion: CXCR4 is modulated in an induced ischemia context implying a possible association with myocardial infarction. Checking of CXCR4 expression in the ischemic changes shows that damage to the heart tissue trigger the secretion of inflammatory chemokine SDF, Followed by it CXCR4 expression in blood cells. These observations suggest that changes in the expression of CXCR4 may be considered a valuable marker for monitoring myocardial infarction.


1. Brown D. Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart. J Ap Phy2003;95: 2510-2518.

2. Kanitz M. Myocardial infarction in young adults: risk factors and clinical features.  J Em Med1996; 14: 139-145.

3. Hearse D. Myocardial ischaemia: can we agree on a definition for the 21st century? Cardiovasc Res 1994; 28: 1737- 1745.

4. Hu X, Dai S, Wu W, Tan W, Zhu X, Mu J, et al. Stromal Cell–Derived Factor-1α Confers Protection AgainstMyocardial /Reperfusion Injury: Role of the Cardiac Stromal Cell–Derived Factor-1α–CXCR4 Axis. Circulation2007;116: 654–663.

5. Penn M, Pastore J, Miller T, Aras. R. SDF-1 in myocardial repair. Gene Ther2012; 19:583–587.

6. Chen J, Chemaly E, Liang L, Kho C, Lee A, Park. J, et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010; 176: 1705-1715.

7. Dai S, Yuan F, Mu J, Li C, Chen N, Guo S, et al. Chronic AMD3100 antagonism of SDF-1α-CXCR4 exacerbates cardiac dysfunction andremodeling after myocardial infarction. J MolCell Cardiol 2010; 49: 587-97.

8. Agarwal U, Ghalayini W, Dong F, Weber K, Zou Y, Rabbany S, et al. Role of Cardiac Myocyte CXCR4 Expression in Development andLeft Ventricular After Acute Myocardial Infarction. Circ Res 2010; 107: 667–676.

9. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura. L, Allendorf D, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. JMolHistol  2004; 35: 233-245.

10. Elmadbouh I, HKh H, Jiang S, Idris N, Lu G, Ashraf M. Ex vivo deliveredstromal cell-derived factor-1alpha promotes stem cell homing andinduces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42:792–803.

11. Frangogiannis N. The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. J Am Coll Cardiol 2011; 58:2424–2426.

12. Saxena A, Fish J, White M, Yu S, Smyth J, Shaw R, et al. Stromal cell-derived factor-1alpha is cardioprotectiveafter myocardial infarction. Circulation2008; 117: 2224-2231.

13. Nazari A, Sadr S, Faghihi M, Imani A, Moghimian M. The cardioprotective effect of different doses of vasopressin (AVP) against ischemia–reperfusion injuries in the anesthetized rat heart. Peptides 2011; 32 : 2459-2466.

14. Walker  M,  Curtis  M,  Hearse  D,  Campbell  R,  Janse  M,  Yellon  D,  et  al.  The Lambeth  Conventions:  guidelines  for  the  study  of  arrhythmias  in  ischaemia infarction,  and  reperfusion.  Cardiovasc  Res 1988; 22:447–455.

15. Ulmer A, Scholz W, Ernst M, Brandt E, Flad H. Isolation and Subfractionation of Human Peripheral Blood Mononuclear Cells (PBMC) by Density Gradient Centrifugation on Percoll. Immunobiology 1984; 166: 238-250.

16. Wu B, Chien E, Mol C. Structures of the CXCR4 chemokine GPCR with small molecule and cyclic peptide antagonists. Science 2010; 330: 1066–1071.

17. Anderson j, Reiser j, Gough W, Nydegger C. Intramyocardial current flow in acute coronary occlusion in the canine heart. Journal of the American College of Cardiology 1983; 1: 436-443.

18. Zhang S, Song X, He M, Yu S. Effect of TGF-β1/SDF-1/CXCR4 signal on BM-MSCs homing in rat heart of ischemia/perfusion injury. Eur rev med pharm sciences. 2016;20:899-905.

19. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cellsduring transplantation in infarcted myocardium.Cardiovasc Res  2008; 77: 134-142.

20. Zakharova L, Mastroeni D, Mutlu N, Molina M, Goldman S, Diethrich E. Transplantation of cardiac progenitor cell sheet onto infracted heart promotes cardiogenesis and improvesfunction. Cardiovasc Res 2010; 10: 340-331.

21. Czarnowska E,Gajerska-Dzieciatkowska M, Kusmierski. K, Lichomski J, Machaj E, Pojda Z, et al. Expression of SDF-1- CXCR4 axis and anti-remodelling effectiveness of foetal- liver stem cell transplantation in the infaracted rat heart. J phy pharma2007; 58:729-744.

22. Cho S, Sun H, Yang J, Jung J, An  J, Cho H, et al. Transplantation of Mesenchymal Stem Cells Over-expressing RANK-Fc or CXCR4 PreventsBone Loss in Ovariectomized Mice. Mol Therapy2009; 17:1979–1987.

23. Luo Y, Zhao X, Zhou X, Ji W. Zhang L, Luo T, et al. Short-term intermittent administration of CXCR4 antagonist AMD3100 facilitates myocardial repair in experimental myocardial infarction. Acta Biochim Biophys Sin2013 ;45: 561–569.

24. Kadivar M, Alijani N, Farahmandfar M, Rahmati S, Ghahhari N, Mahdian R. Effect of acute hypoxia on CXCR4 gene expression in C57BL/6 mouse bone marrow-derived mesenchymal stem cells. Adv Biomed Res 2014;3:222.

25. Zhang M, Mal N, kiedrowski M, Chacko M, Askari A, Popovic Z, et al. SDF-1expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J  2007; 21:3197–207.

26. Semenza. G. HIF-1: mediatior of physiological andpathophysiological responses to hypoxia. I APPl Physiol  2000; 88: 1474-1480.

27. Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.

28. Kalogeris T, Baines C, Krenz M, Korthuls R. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298: 229-317.

29. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regene-rate infarcted
myocardium. Nature 2001; 410: 701–705. 

30. Tang X, Rokosh G, Sanganalmath S, Yuan F, Sato H, Mu J et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 2010; 121: 293–305. 

31. Sanz-Ruiz R, GIE A, Fernández S, Fernández P, Fernández-Avilés F. Phases i-iii clinical trials using adult stem cells. Stem Cells Int 2010; 2010: 579142. 

32. Traverse J, McKenna D, Harvey K, Jorgenso B, Olson R, Bostrom N et al. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. Am Heart J 2010; 160: 428–434

33. Hare J, Fishman J, Gerstenblith G, DiFede V, Zambrano J, Suncion V et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA  2012; 308: 2369–2379. 

34. He H, Han F. Clinical studies on stem cells therapy for ischemic heart diseases. Adv Cardiovasc Dis 2012; 33: 181–184.